2023
S1564 Lessons in Monitoring Chelation Therapy in “Stable” Wilson Disease Patients Screened for a Randomized Trial
Medici V, Peralta R, Kamlin C, Heifets M, Schilsky M. S1564 Lessons in Monitoring Chelation Therapy in “Stable” Wilson Disease Patients Screened for a Randomized Trial. The American Journal Of Gastroenterology 2023, 118: s1180-s1181. DOI: 10.14309/01.ajg.0000955896.28554.ec.Peer-Reviewed Original Research
2022
FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trial
Kamlin C, Schilsky M, Ott P, Weiss K, Zuin M, Poujois A, Ala A, D’Hollander K. FRI297 Defining the boundaries for “stability” in Wilson disease patients on maintenance chelation therapy: lessons from the CHELATE trial. Journal Of Hepatology 2022, 77: s539. DOI: 10.1016/s0168-8278(22)01402-7.Peer-Reviewed Original Research
2019
Chapter 15 General Considerations and the Need for Liver Transplantation
Camarata M, Weiss K, Schilsky M. Chapter 15 General Considerations and the Need for Liver Transplantation. 2019, 173-182. DOI: 10.1016/b978-0-12-811077-5.00015-3.Peer-Reviewed Original ResearchAcute liver failureLiver transplantationWilson's diseaseLiver failureMedical therapyUse of LTEnd-stage liver diseaseLive donor transplantsOnly viable treatment optionViable treatment optionCombination of dietRare autosomal recessive disorderAlternative transplant strategyWilson's disease patientsAutosomal recessive disorderAuxiliary transplantInitial presentationLiver diseaseMedical managementNeurological symptomsTransplant strategiesTreatment optionsDisease patientsDonor poolDisease progression
2018
Treating Other Symptoms of Wilson Disease: The Liver
Camarata M, Schilsky M. Treating Other Symptoms of Wilson Disease: The Liver. Clinical Gastroenterology 2018, 87-106. DOI: 10.1007/978-3-319-91527-2_5.Peer-Reviewed Original ResearchWilson's diseaseLiver diseaseLiver cancerEnd-stage liver diseaseAcute liver failureMinority of patientsTime of diagnosisRoutine laboratory testingWilson's disease patientsPortal hypertensionInflamed liverLiver failurePrompt initiationAppropriate therapyChronic inflammationDisease patientsFamily screeningDisease progressionTimely initiationSevere symptomsPathological accumulationCirrhosisPatientsDiseaseLiverA comparison of resting-state functional magnetic resonance imaging between Neurological and Liver-only affected Wilson’s Disease patients (P4.014)
Nalamada K, Tinaz S, Arora J, Vives-Rodriguez A, Constable T, Schilsky M, Robakis D. A comparison of resting-state functional magnetic resonance imaging between Neurological and Liver-only affected Wilson’s Disease patients (P4.014). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p4.014.Peer-Reviewed Original Research
2016
PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations
Weiss K, Ala A, Askari F, Bega D, Bronstein J, Czlonkowska A, Ferenci P, Nicholl D, Schilsky M. PS020 An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations. Journal Of Hepatology 2016, 64: s145-s146. DOI: 10.1016/s0168-8278(16)00033-7.Peer-Reviewed Original Research
2015
P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patients
Weiss K, Askari F, Ferenci P, Czlonkowska A, Bronstein J, Schilsky M, Clark D, Hansson J. P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patients. Journal Of Hepatology 2015, 62: s847. DOI: 10.1016/s0168-8278(15)31492-6.Peer-Reviewed Original Research